ShareValue scores for VNRX: Valuation 49, Quality 19, Growth 73, Health 48.

VNRX
NYSE American

Volitionrx Ltd

$0.77(-3.65%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 19%
Valuation
49
Fair Value
Price vs Value
Quality
19
Weak
Business Strength
Growth
73
Strong
Revenue & Earnings
Health
48
Moderate
Financial Stability
Momentum
17
Bearish
Price Trend

Company Details

About

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026